KEYMED BIOSCIENCES -0001 (64Z) — Net Asset Quality Index
KEYMED BIOSCIENCES -0001 (64Z) has a Net Asset Quality Index of 65.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €4.22 Billion minus total liabilities of €1.44 Billion yields net assets of €2.77 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 64Z financial resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
KEYMED BIOSCIENCES -0001 Net Asset Quality Index Over Time (2021–2025)
This chart shows how KEYMED BIOSCIENCES -0001's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 65.8%, representing net assets of €2.77 Billion against total assets of €4.22 Billion EUR. See 64Z working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for KEYMED BIOSCIENCES -0001 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for KEYMED BIOSCIENCES -0001 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see how much is KEYMED BIOSCIENCES -0001 worth.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 65.8% | €2.77 Billion | €4.22 Billion | €1.44 Billion | ▲ +0.1 pp |
| 2024 | 65.7% | €2.48 Billion | €3.77 Billion | €1.29 Billion | ▼ -11.2 pp |
| 2023 | 76.9% | €2.99 Billion | €3.88 Billion | €896.11 Million | ▼ -8.0 pp |
| 2022 | 84.9% | €3.34 Billion | €3.93 Billion | €593.10 Million | ▼ -7.7 pp |
| 2021 | 92.7% | €3.65 Billion | €3.93 Billion | €289.07 Million | — |